4507 Stock Overview
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
Shionogi & Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥6,228.00 |
52 Week High | JP¥8,137.00 |
52 Week Low | JP¥5,718.00 |
Beta | 0.35 |
11 Month Change | -13.92% |
3 Month Change | -17.81% |
1 Year Change | 5.22% |
33 Year Change | 9.69% |
5 Year Change | 0.89% |
Change since IPO | 560.45% |
Recent News & Updates
Shareholder Returns
4507 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -0.8% | 3.6% | 2.4% |
1Y | 5.2% | 16.4% | 24.6% |
Return vs Industry: 4507 underperformed the JP Pharmaceuticals industry which returned 16.4% over the past year.
Return vs Market: 4507 underperformed the JP Market which returned 24.6% over the past year.
Price Volatility
4507 volatility | |
---|---|
4507 Average Weekly Movement | 4.6% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 3.8% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4507 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4507's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1878 | 4,959 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
4507 fundamental statistics | |
---|---|
Market cap | JP¥1.77t |
Earnings (TTM) | JP¥162.03b |
Revenue (TTM) | JP¥435.08b |
10.9x
P/E Ratio4.1x
P/S RatioIs 4507 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4507 income statement (TTM) | |
---|---|
Revenue | JP¥435.08b |
Cost of Revenue | JP¥57.60b |
Gross Profit | JP¥377.48b |
Other Expenses | JP¥215.45b |
Earnings | JP¥162.03b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 29, 2024
Earnings per share (EPS) | 571.55 |
Gross Margin | 86.76% |
Net Profit Margin | 37.24% |
Debt/Equity Ratio | 0% |
How did 4507 perform over the long term?
See historical performance and comparison